Drug developer NRX up on smaller third-quarter loss

NRX Pharmaceuticals

14/11/2022 13:47

** Shares of NRX Pharmaceuticals Inc.  NRXP.O  rise ~3% to
$1.03 in premarket trading - set to open at its highest since
July this year
    ** Co's losses in the third quarter narrow to 14 cents per
share from a loss of 72 cents per share a year ago  
    ** NRXP loss is in line with Wall St estimates - Refinitiv
data
    ** Losses decrease with a reduction in expenses - mainly
research costs for its COVID-19 drug and stock based
compensations 
    ** Co expects to start late-stage trial for its depression
drug by the end of the year 
    ** Earlier this year, co appointed Stephen Willard as CEO 
    ** As of last close, the stock is down ~79% 
 (Reporting by Anirban Chakroborti in Bengaluru)
 ((Anirban.Chakroborti@thomsonreuters.com;))